Summary for the test article
Mind Moments Podcast
Metronomic Capecitabine Continues Efficacy With Pyrotinib in HER2+ Advanced Breast Cancer
December 4th 2023Results from an international phase 2 study show that using metronomic capecitabine in combination with the tyrosine kinase inhibitor pyrotinib continued to have promising efficacy results for patients with HER2-positive metastatic breast cancer.
Read More